Browse > Article
http://dx.doi.org/10.13160/ricns.2017.10.2.105

Molecular Docking Study of Urotension-2 Receptor (UTS2R)  

Sathya., B (Department of Bioinformatics, School of Bioengineering, SRM University)
Publication Information
Journal of Integrative Natural Science / v.10, no.2, 2017 , pp. 105-109 More about this Journal
Abstract
Urotensin-2 receptor (UTS2R) is the most potent vasoconstrictor and plays a major role in the pathophysiology of various cardiovascular diseases and becomes a potential target for human pharmacotherapy. Hence, we have performed molecular docking of six antagonists with different inhibitory activity against UTS2R into its binding site. The binding mode of these antagonists was obtained using Surflex dock program interfaced in Sybyl-X2.0. The residues such as GLN278, THR304, TYR305, THR300, LEU299, CYS302, ASP47, TYR100 and THR304 are found in interaction between UTS2R and its antagonists. This study could be useful for identifying and analyzing the important residues involved in binding site of UTS2R receptor.
Keywords
UTS2R; Molecular Docking;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Q. Liu, S.-S. Pong, Z. Zeng, Q. Zhang, A. D. Howard, D. L. Williams, M. Davidoff, R. Wang, C. P. Austin, T. P. McDonald, C. Bai, S. R. George, J. F. Evans, and C. T. Caskey, "Identification of urotension II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14", Biochem. Biophys. Res. Commun., Vol. 266, pp. 174-178, 1999.   DOI
2 M. Mori, T. Sugo, M. Abe, Y. Shimomura, M. Kurihara, C. Kitada, K. Kikuchi, Y. Shintani, T. Kurokawa, H. Onda, O. Nishimura, and M. Fujino, "Urotensin II is the endogenous ligand of a G-proteincoupled orphan receptor, SENR (GPR14)", Biochem. Biophys. Res. Commun., Vol. 265, pp. 123-129, 1999.   DOI
3 A. Carotenuto, P. Grieco, E. Novellino, and P. Rovero, "Urotensin- II receptor peptide agonists", Med Res Rev, vol. 24, pp. 577-588, 2004.   DOI
4 G. Thanassoulis, T. Huyhn, and A. Giaid, "Urotensin II and cardiovascular diseases", Peptides, Vol. 25, pp. 1789-1794, 2004.   DOI
5 R. S. Ames, H. M. Sarau, J. K. Chambers, R. N. Willette, N. V. Aiyar, A. M. Romanic, C. S. Louden, J. J. Foley, C. F. Sauermelch, R. W Coatney, Z. Ao, J. Disa, S. D. Holmes, J. M. Stadel, J. D. Martin, W. S. Liu, G. I. Glover, S. Wilson, D. E. McNulty, C. E. Ellis, N. A. Elshourbagy, U. Shabon, J. J. Trill, D. W. Hay, E. H. Ohlstein, D. J. Bergsma, and S. A. Douglas, "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14", Nature, Vol. 401, pp. 282-286, 1999.   DOI
6 A. M. D. Watson and C. N. May, "Urotensin II, a novel peptide in central and peripheral cardiovascular control", Peptides, Vol. 25, pp. 1759-1766, 2004.   DOI
7 J. J. Maguire, R. E. Kuc, and A. P. Davenport, "Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1", Br. J. Pharmacol., Vol. 131, pp. 441-446, 2000.   DOI
8 M. Matsushita, M. Shichiri, T. Imai, M. Iwashina, H. Tanaka, N. Takasu, and Y Hirata, "Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues", J. Hypertens., Vol. 19, pp. 2185-2190, 2001.   DOI
9 W. Kemp, S. Roberts, and H. Krum, "Increased circulating urotensin II in cirrhosis: potential implications in liver disease", Peptides, Vol. 29, pp. 868-872, 2008.   DOI
10 F. D. Russell and P. Molenaar, "Cardiovascular actions of human urotensin II: considerations for hypertension", Naunyn Schmiedebergs Arch. Pharmacol., Vol. 369, pp. 271-273, 2004.   DOI
11 S. A. Douglas, L. Tayara, E. H. Ohlstein, N. Halawa, and A. Giaid, "Congestive heart failure and expression of myocardial urotension II", Lancet, Vol. 359, pp. 1990-1997, 2002.   DOI
12 K. Totsune, K. Takahashi, Z. Arihara, M. Sone, F. Satoh, S. Ito, Y. Kimura, H. Sasano, and O. Murakami, "Role of urotensin II in patients on dialysis", Lancet, Vol. 358, pp. 810-811, 2001.   DOI
13 K. Takahashi, K. Totsune, O. Murakami, Z. Arihara, T. Noshiro, Y. Hayashi, and S. Shibahara, "Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II", Peptides, Vol. 24, pp. 301-306, 2003.   DOI
14 A. M. Richards, M. G. Nicholls, J. G. Lainchbury, S. Fisher, and T. G. Yandle, "Plasma urotensin II in heart failure", Lancet, Vol. 360, pp. 545-546, 2002.   DOI
15 F. D. Russell, D. Meyers, A. J. Galbraith, N. Bett, I. Toth, P. Kearns, and P. Molenaar, "Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure", Am. J. Physiol. Heart Circ. Physiol., Vol. 285, pp. H1576-H1581, 2003.   DOI
16 B. Sathya, "Homology modelling of urotensin-2 receptor (UTS2R): potential target for human pharmacotherapy", J. Chosun Natural Sci., Vol. 9, pp. 185-189, 2016.   DOI
17 M. Clozel, C. Binkert, M. Birker-Robaczewska, C. Boukhadra, S. S. Ding, W. Fischli, P. Hess, B. Mathys, K. Morrison, C. Müller, C. Muller, O. Nayler, C. Qiu, M. Rey, M. W. Scherz, J. Velker, T. Weller, J. F. Xi, and P. Ziltener, Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System, J. Pharmacol. Exp. Ther., Vol. 311, pp. 204-212, 2004.   DOI
18 SYBYL Software, Version X 2.0,Tripos Associates Inc, St. Louis, USA.
19 J. Jin, M. An, A. Sapienza, N. Aiyar, D. Naselsky, H. M. Sarau, J. J. Foley, K. L. Salyers, S. D. Knight, R. M. Keenan, R. A. Rivero, D. Dhanak, and S. A. Douglas, Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides, Bioorg. Med. Chem. Lett., Vol. 18, pp. 3950-3954, 2008.   DOI
20 E. C. Lawson, D. K. Luci, S. Ghosh, W. A. Kinney, C. H. Reynolds, J. Qi, C. E. Smith, Y. Wang, L. K. Minor, B. J. Haertlein, T. J. Parry, B. P. Damiano, and B. E. Maryanoff, Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits, J. Med. Chem., Vol. 52, pp. 7432-7445, 2009.   DOI
21 S. A. Douglas, D. J. Behm, N. V. Aiyar, D. Naselsky, J. Disa, D. P. Brooks, E. H. Ohlstein, J. G. Gleason, H. M. Sarau, J. J. Foley, P. T. Buckley, D. B. Schmidt, W. E. Wixted, K. Widdowson, G. Riley, J. Jin, T. F. Gallagher, S. J. Schmidt, L. Ridgers, L. T. Christmann, R. M. Keenan, S. D. Knight and D. Dhanak, Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375, Br. J. Pharmacol., Vol. 145, pp. 620-635, 2005.   DOI
22 A. N. Jain, "Scoring non-covalent protein-ligand interactions: a continuous differentiable function tuned to compute binding", J. Comput. Aided Mol. Des., Vol. 10, pp. 427-440, 1996.   DOI
23 S. Flohr, M. Kurz, E. Kostenis, A. Brkovich, A. Fournier and T. Klabunde, Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II, J. Med. Chem., Vol. 45, pp. 1799-1805, 2002.   DOI
24 E. Rakowski, G. S. Hassan, D. Dhanak, E. H. Ohlstein, S. A. Douglas, and A. Giaid, A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker, J. Mol. Cell. Cardiol., Vol. 39, pp. 785-791, 2005.   DOI
25 A. N. Jain, "Scoring functions for protein-ligand docking", Curr. Protein Pept. Sci., Vol. 7, pp. 407-420, 2006.   DOI
26 N. Santhosh Kumar and M. Thirumurthy, "3D-QSAR studies of 8-substituted-2-aryl-5-alkylaminoquinolines as Corticotropin-releasing factor-1 receptor antagonists", J. Chosun Natural Sci., Vol. 8, pp. 176-183, 2015.   DOI
27 N. Santhosh Kumar and M. Thirumurthy, "Comparative Molecular Similarity Indices Analysis (CoMSIA) of 8-substituted-2-aryl-5-alkylaminoquinolines as Corticotropin-releasing factor-1 Receptor Antagonists", J. Chosun Natural Sci., Vol. 9, pp. 241-248, 2016.   DOI